search
Back to results

Diabetic Foot Ulcer Study on Topical Interventions (DFU)

Primary Purpose

Diabetic Foot

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Acticoat absorbent
Honey gel sheet
Jelonet
Sponsored by
Queen Elizabeth Hospital, Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot focused on measuring foot ulcer and honey and silver

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of type 2 diabetes mellitus and
  • Age 40 or above with foot ulcer and
  • Ulcer with size equals or larger than 1 cm in diameter and
  • Ulcer located at or below malleolar region of foot and
  • Superficial ulcer, ulcer penetrates to tendon or capsule and
  • Ulcer without infection, mild and moderate infection and
  • Subject with no foreseeable surgery within 12-week study period

Exclusion Criteria:

  • HbA1c level ≥ 10% or
  • Severe ischemia with ankle-brachial index (ABI) ≤ 0.4 or
  • Ulcer deep into bone and joint or
  • Osteomyelitis or
  • Severe ulcer infection or
  • Known allergy to manuka honey/ nanocrystalline silver or
  • Known case of venous ulcer or varicose vein or
  • Known case of benign or malignant tumor or
  • Known to have any auto-immune disease or
  • A condition requiring medication that affects the immune response or
  • Participation in other experimental treatment studies or
  • Pregnancy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Other

    Arm Label

    Acticoat absorbent

    Honey gel sheet

    Jelonet

    Arm Description

    Apply Acticoat absorbent onto the ulcer

    Apply Honey gel sheet onto the ulcer

    Apply Jelonet onto the ulcer

    Outcomes

    Primary Outcome Measures

    Number of Participants With Complete Healing of Ulcer During the Observation Period
    The number of participants have absence of a visible wound achieved by complete epithelialization

    Secondary Outcome Measures

    Change in Ulcer Size
    the Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4
    the Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4
    the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4

    Full Information

    First Posted
    October 11, 2015
    Last Updated
    April 5, 2019
    Sponsor
    Queen Elizabeth Hospital, Hong Kong
    Collaborators
    The Hong Kong Polytechnic University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02577900
    Brief Title
    Diabetic Foot Ulcer Study on Topical Interventions
    Acronym
    DFU
    Official Title
    Randomized, Controlled Study of Nanocrystalline Silver, Manuka Honey and Conventional Dressing in Healing Diabetic Foot Ulcer
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2013 (undefined)
    Primary Completion Date
    August 2015 (Actual)
    Study Completion Date
    August 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Queen Elizabeth Hospital, Hong Kong
    Collaborators
    The Hong Kong Polytechnic University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to determine whether nanocrystalline silver dressing, manuka honey dressing and conventional dressing are effective in the treatment of diabetic foot ulcer.
    Detailed Description
    Patient flow The target subjects were screened in the orthopedic department of two regional hospitals and one general outpatient clinic (GOPD). Those eligible potential subjects were recruited after they discharged from hospital according to the selection criteria. All the subjects were referred and intervened in an orthopedic nurse clinic a regional hospital. The subjects were randomized into three groups through a fixed block of 10 by online software. A sequence of assignment was generated and put into a sealed envelope by a research assistant. The investigator did not involve in randomization process and allocation sequence. The subjects were enrolled and allocated to different treatment arms according to the allocation sequence. Data collection Outcome assessor blinding was employed in this study. A research assistant was responsible for measuring the wound size and taking clinical photo. In every clinical visit, the research assistant waited outside the clinic until the removal and proper cleansing of the wound by the first author so that she unaware of the topical treatment option. The subjects would be discontinued follow up when the wound was completely healed or till the end of 12-week study period. Intervention All participants attended the nurse clinic for follow-up by the first author (nurse consultant) weekly in the first four week and then biweekly till 12 weeks of follow up period. They were nine clinical attendances totally. At each visit, sharp debridement for the non-viable tissue and stimulation of the vascularity on the avascular tissue were performed if needed by the first author. Then, he applied the topical dressing according to randomization sequence. Statistical analysis All the analysis will be carried out according to the intention-to-treat principle. SPSS Statistics for Mac version 22 (SPSS Inc, Chicago, Illinois) was used for data analysis. Comparison would be made among groups by Fisher's exact test for nominal data and Kruskal-Wallis test for ordinal and scale data. The complete ulcer healing was compared among groups by Kaplan-Meier estimates. General estimating equation (GEE) was used to compare the ulcer size reduction rate, the wound fluid concentration of matrix metalloproteinase -9 (MMP9), tumor necrosis factor alpha (TNF-α) and interleukin-1 alpha (IL-1α) among groups. Statistical significance was set at p < 0.05 for all tests. Sample size calculation The probability of non-healing (p1) on nanocrystalline silver (nAg) group = 0.20 The probability (p2) of non-healing on manuka honey (MH)/conventional group = 0.50 The alpha (α) value was 0.05 and power (1-β) was 0.8 Ratio of sample size per group was 1:1 Therefore, the total sample subjects for 2 groups were 77. Each group needed 39 subjects. For 3 groups, the total numbers of subjects were 117. From the experience, 10% of patients were loss to follow up. The actual numbers of subjects needs were 129. i.e. 43 subjects per group. Data quality assurance In order to ensure the data quality, a research assistant was assigned to verify the source document and other trial records were accurate, complete, kept up-to-date and maintained. The student investigator trained the research assistant in the data quality assurance process. The student investigator also checked the data entry sheet with raw data every month. The responsibilities of research assistant were listed as follows. Check the accuracy and completeness on the case screening form and consent form. Verify the laboratory data in the case record form (CRF) were consistent with the corresponding laboratory result. Verify the inter-current illness was reported on the CRF. Verify all withdrawals and dropouts of enrolled subjects from this trial were reported and explained on the CRF. If there was any missing data or data inconsistency, the research assistant was clarified the data with the internal electronic record of the hospital. Handling of missing data The nature of this study was the multiple observations of subjects in regular censored points. Thus, the missing clinical data was handled by the last observation carried forward. For those laboratory data, statistical method of general estimating equation was used for the analysis on the repeated measures among groups. The missing data was under the missing completely at random (MCAR) assumption. Therefore, the laboratory missing data did not need to make estimation in the present study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetic Foot
    Keywords
    foot ulcer and honey and silver

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    31 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Acticoat absorbent
    Arm Type
    Experimental
    Arm Description
    Apply Acticoat absorbent onto the ulcer
    Arm Title
    Honey gel sheet
    Arm Type
    Active Comparator
    Arm Description
    Apply Honey gel sheet onto the ulcer
    Arm Title
    Jelonet
    Arm Type
    Other
    Arm Description
    Apply Jelonet onto the ulcer
    Intervention Type
    Device
    Intervention Name(s)
    Acticoat absorbent
    Other Intervention Name(s)
    nanocrystalline silver alginate
    Intervention Description
    Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
    Intervention Type
    Device
    Intervention Name(s)
    Honey gel sheet
    Other Intervention Name(s)
    Manuka honey alginate
    Intervention Description
    Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
    Intervention Type
    Device
    Intervention Name(s)
    Jelonet
    Other Intervention Name(s)
    paraffin tulle
    Intervention Description
    Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
    Primary Outcome Measure Information:
    Title
    Number of Participants With Complete Healing of Ulcer During the Observation Period
    Description
    The number of participants have absence of a visible wound achieved by complete epithelialization
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Change in Ulcer Size
    Time Frame
    12 weeks
    Title
    the Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4
    Time Frame
    Week 1, Week 4
    Title
    the Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4
    Time Frame
    Week 1, Week 4
    Title
    the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4
    Time Frame
    Week 1, Week 4

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: History of type 2 diabetes mellitus and Age 40 or above with foot ulcer and Ulcer with size equals or larger than 1 cm in diameter and Ulcer located at or below malleolar region of foot and Superficial ulcer, ulcer penetrates to tendon or capsule and Ulcer without infection, mild and moderate infection and Subject with no foreseeable surgery within 12-week study period Exclusion Criteria: HbA1c level ≥ 10% or Severe ischemia with ankle-brachial index (ABI) ≤ 0.4 or Ulcer deep into bone and joint or Osteomyelitis or Severe ulcer infection or Known allergy to manuka honey/ nanocrystalline silver or Known case of venous ulcer or varicose vein or Known case of benign or malignant tumor or Known to have any auto-immune disease or A condition requiring medication that affects the immune response or Participation in other experimental treatment studies or Pregnancy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Tsang Ka Kit, Master
    Organizational Affiliation
    Queen Elizabeth Hospital, Hong Kong
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Diabetic Foot Ulcer Study on Topical Interventions

    We'll reach out to this number within 24 hrs